anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The ability to reliably discriminate vocal expressions of emotion is crucial to engage in successful social interactions. This process is arguably more crucial for blind individuals, since they cannot extract social information from faces and bodies, and therefore chiefly rely on voices to infer the emotional state of their interlocutors. Blind have demonstrated superior abilities in several aspects of auditory perception, but research on their ability to discriminate vocal features is still scarce and has provided unclear results. Here, we used a gating psychophysical paradigm to test whether early blind people would differ from individually matched sighted controls at the recognition of emotional expressions. Surprisingly, blind people showed lower performance than controls in discriminating specific vocal emotions. We presented segments of nonlinguistic emotional vocalizations of increasing duration (100-400 ms), portraying five basic emotions (fear, happy, sad, disgust, and angry), and we asked our participants for an explicit emotion categorization task. We then calculated sensitivity indices and confusion patterns of their performance. We observed better performance of the sighted group in the discrimination of angry and fearful expression, with no between-group differences for other emotions. This result supports the view that vision plays a calibrating role for specific threat-related emotions specifically. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
The invention relates to a hernia patch solid-supported with antibiotics and a preparation method. The antibiotic hernia patch solid-supported with drug-loaded microspheres comprises drug-loaded microspheres, a patch, and a supporting agent. The sandwich-type antibiotic hernia patch comprises a patch layer, a drug layer, and a film layer. The antibiotic hernia patch solid-supported with drug-loaded microspheres is prepared by solid-supporting the drug-loaded microspheres onto the surface of the patch material by the supporting agent. The drug-loaded microspheres are loaded with water-soluble drugs by a solvent evaporation method. The sandwich-type antibiotic hernia patch is prepared by sandwiching the drug layer between the patch layer and the film layer through a layer-by-layer superposition principle. The antibiotic hernia patch of the invention has a simple and practical preparation method, is suitable for different clinical medication requirements, has obvious slow release performance, has significant antibiotic effect in rats, solves the problem of acute and delayed infection after herniorrhaphy, has good market prospects, and is worthy of popularization and utilization.
PROBLEM TO BE SOLVED: To obtain a tooth surface coating agent having a more excellent tooth surface coating action than that of a conventional one, excellent adsorbing action of other components such as a germicide, on a tooth surface, useful as a component for a composition for oral cavity by making the coating agent include a fatty acid salt. SOLUTION: This tooth surface coating agent comprises preferably 0.05-10 wt.% more preferably 0.1-5 wt.%, based on the total weight of the tooth coating agent, of a fatty acid salt. A 10-20C fatty acid salt may be cited as the fatty acid salt. An unsaturated higher fatty acid salt of the formula R-COO-.X (R is CnH2n+1; (n) is 9-19; X is Na+, K+ or NH4+) is preferable. To be concrete sodium salt, potassium salt, ammonium salt, or the like, of oleic acid, caproleic acid, lauroleic acid, myristoleic acid, palimtoleic acid and elaidic acid may be cited as the fatty acid salt. Especially sodium oleate is preferable.
Subjects who participated in the control arm of study #09-1 who are not treatment failures and have completed 12 months of the study. These subjects will have the EndoBarrier device implanted for 12 months.
Radiotherapy-induced cardiac toxicity and consequent diseases still represent potential severe late complications for many cancer survivors who undergo therapeutic thoracic irradiation. We aimed to assess the phenotypic and paracrine features of resident cardiac mesenchymal stromal cells (CMSCs) at early follow-up after the end of thoracic irradiation of the heart as an early sign and/or mechanism of cardiac toxicity anticipating late organ dysfunction. Resident CMSCs were isolated from a rat model of fractionated thoracic irradiation with accurate and clinically relevant heart dosimetry that developed delayed dose-dependent cardiac dysfunction after 1 year. Cells were isolated 6 and 12 weeks after the end of radiotherapy and fully characterized at the transcriptional, paracrine, and functional levels. CMSCs displayed several altered features in a dose- and time-dependent trend, with the most impaired characteristics observed in those exposed in situ to the highest radiation dose with time. In particular, altered features included impaired cell migration and 3D growth and a and significant association of transcriptomic data with GO terms related to altered cytokine and growth factor signaling. Indeed, the altered paracrine profile of CMSCs derived from the group at the highest dose at the 12-week follow-up gave significantly reduced angiogenic support to endothelial cells and polarized macrophages toward a pro-inflammatory profile. Data collected in a clinically relevant rat model of heart irradiation simulating thoracic radiotherapy suggest that early paracrine and transcriptional alterations of the cardiac stroma may represent a dose- and time-dependent biological substrate for the delayed cardiac dysfunction phenotype observed in vivo.
BACKGROUND: Multi-faceted evidence from a range of cancers suggests strongly that de novo expression of voltage-gated sodium channels (VGSCs) plays a significant role in driving cancer cell invasiveness. Under hypoxic conditions, common to growing tumours, VGSCs develop a persistent current (INaP) which can be blocked selectively by ranolazine.
METHODS: Several different carcinomas were examined. We used data from a range of experimental approaches relating to cellular invasiveness and metastasis. These were supplemented by survival data mined from cancer patients.
RESULTS: In vitro, ranolazine inhibited invasiveness of cancer cells especially under hypoxia. In vivo, ranolazine suppressed the metastatic abilities of breast and prostate cancers and melanoma. These data were supported by a major retrospective epidemiological study on breast, colon and prostate cancer patients. This showed that risk of dying from cancer was reduced by ca.60% among those taking ranolazine, even if this started 4 years after the diagnosis. Ranolazine was also shown to reduce the adverse effects of chemotherapy on heart and brain. Furthermore, its anti-cancer effectiveness could be boosted by co-administration with other drugs.
CONCLUSIONS: Ranolazine, alone or in combination with appropriate therapies, could be reformulated as a safe anti-metastatic drug offering many potential advantages over current systemic treatment modalities.
Patients will be recruited following the inclusion criteria: any patient with a diagnosis of brain tumour, age ranging from 18 with no upper limit, who will agree to the operation and to take part of the present study, will be enrolled. During surgery, multispectral and/or hyper spectral acquisition of images from the surgical field will be performed. Each patient will have an average acquisition of 6 datasets. As each dataset will correspond to an image, this will be divided into many reading regions (from 10 to 20) for a total of approximatively 60 measurements per patient.
Ginsana-115 (Panax Ginseng formulation obtained from Boehringer Ingelheim Pharmaton Inc. Switzerland )is available in oral dosage form of capsules. Two dosages of Ginsana-115 will be tested: 100 mg once daily oral dosage ( 1 100-mg Ginsana-115 capsule) and 200 mg once daily dosage ( 2 100-mg Ginsana-115 capsule). The total duration of each dosage is 8 weeks.
Postprandial, or meal-related, symptoms, such as abdominal pain, early satiation, fullness or bloating, are often reported by patients with disorders of gut-brain interaction, including functional dyspepsia (FD) or irritable bowel syndrome (IBS). We propose that postprandial symptoms arise via a distinct pathophysiological process. A physiological or psychological insult, for example, acute enteric infection, leads to loss of tolerance to a previously tolerated oral food antigen. This enables interaction of both the microbiota and the food antigen itself with the immune system, causing a localised immunological response, with activation of eosinophils and mast cells, and release of inflammatory mediators, including histamine and cytokines. These have more widespread systemic effects, including triggering nociceptive nerves and altering mood. Dietary interventions, including a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols, elimination of potential food antigens or gluten, IgG food sensitivity diets or salicylate restriction may benefit some patients with IBS or FD. This could be because the restriction of these foods or dietary components modulates this pathophysiological process. Similarly, drugs including proton pump inhibitors, histamine-receptor antagonists, mast cell stabilisers or even tricyclic or tetracyclic antidepressants, which have anti-histaminergic actions, all of which are potential treatments for FD and IBS, act on one or more of these mechanisms. It seems unlikely that food antigens driving intestinal immune activation are the entire explanation for postprandial symptoms in FD and IBS. In others, fermentation of intestinal carbohydrates, with gas release altering reflex responses, adverse reactions to food chemicals, central mechanisms or nocebo effects may dominate. However, if the concept that postprandial symptoms arise from food antigens driving an immune response in the gastrointestinal tract in a subset of patients is correct, it is paradigm-shifting, because if the choice of treatment were based on one or more of these therapeutic targets, patient outcomes may be improved.
This is a randomized (study drug assigned by chance), multi-center (when more than one hospital or medical school team works on a medical research study), double-blind (neither physician nor participant knows the name of the assigned drug), placebo-control (participants are randomly assigned to a test treatment or to an identical-appearing treatment that does not contain the test drug), and parallel-group (each group of participant will be treated at the same time) comparison study in Japanese participants with chronic pain due to painful diabetic peripheral neuropathy or postherpetic neuralgia. The duration of study will be 14 weeks. The study consists of 3 parts: Screening (1 Week before study commences on Day 1); Treatment (12 weeks and will include titration period \[from the initiation of the study treatment to determination of the individual's maintenance dose\] and maintenance period \[from completion of the titration period up to12 week\]); and Follow-up (1 Week). Tapentadol hydrochloride ER oral tablet or matching placebo will be administered twice daily for 12 weeks. Efficacy of the participants will primarily be evaluated through Numerical Rating Scale (NRS). Participants' safety will be monitored throughout the study.
This group will receive up to 4 recall messages (both letters and computer-generated phone messages) reminding them to get their vaccines. There are 4 separate study groups: 1) private pediatric patients 2) public pediatric patients 3) school-based health center patients and 4) family medicine patients.
AbstractMorning Report is a time-honored tradition where physicians-in-training present cases to their colleagues and clinical experts to collaboratively examine an interesting patient presentation. The Morning Report section seeks to carry on this tradition by presenting a patient's chief concern and story, inviting the reader to develop a differential diagnosis and discover the diagnosis alongside the authors of the case. This report examines the story of a 59-year-old man who initially had a sore throat, a truncal rash, and fever. Two weeks later, arthralgias and abrupt bilateral hearing loss developed. Using questions, physical examination, and testing, an illness script for the presentation emerges. As the clinical course progresses, the differential is refined until a diagnosis is made.
A centralized pharmacy validates a drug prescribed by a physician for a patient to ensure that the prescribed drug is a safe and cost effective treatment for the patient. The centralized pharmacy accesses the medical history of the patient, drug information of the prescribed drug, the insurance health plan purchased by the patient, as well as drug abuse information. The centralized pharmacy performs the validation process using the accessed information. If the centralized pharmacy successfully validates the prescribed drug, the centralized pharmacy physically dispatches the prescribed drug to the patient. Alternatively, if the centralized pharmacy determines that the prescribed drug fails the validation process, the centralized pharmacy can identify an alternate drug and validates the alternate drug. Therefore, the centralized pharmacy can automatically replace the prescribed drug with a more appropriate, alternate drug and can dispatch the alternate drug to the patient.
Patients will receive 1 dose of rituximab, 4 doses of bortezomib and plasmapheresis. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, and 11. For those patients who go on to Stage 2 of desensitization, bortezomib will be administered via IV push over 3-5 seconds during the pre-transplant period on days 32, 35, 39, 42. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
The invention discloses a chickpea protein source DPP-IV inhibitory peptide and application thereof, and belongs to the technical field of development of food-borne active peptides. The DPP-IV inhibitory peptide is rapidly screened by utilizing the polypeptimics, various screening conditions and the molecular docking technology, so that the defects of time and labor consumption caused by gradual separation and purification are overcome. The invention effectively obtains high DPP IV inhibitory activity, high antioxidant activity and high Fe from chickpea protein through neutral protease enzymolysis  2+  The chickpea protein hydrolysate with chelating activity is subjected to enzymolysis by alkaline protease to obtain the chickpea protein hydrolysate with cholesterol micelle solubility inhibition activity, and the chickpea protein hydrolysate with high ACE inhibition activity is obtained by enzymolysis by papain. The mode of action of the high-activity DPP IV inhibitory peptide IAIPPGIPYW and DPP IV is competitive-non-competitive mixed inhibition, and the high-activity DPP IV inhibitory peptide IAIPPGIPYW and DPP IV have extremely high DPP-IV inhibitory activity and IC  50  At 12.43. Mu.M (14.00. Mu.g/ml).
The invention relates to an application of IL-22 dimer in the preparation of intravenous injection drugs. Specifically, the invention provides a method for applying IL-22 dimer to an individual (e.g. a human). The method comprises a step of determining the dosage of IL-22 dimer for intravenous injection on an individual. The dosage of IL-22 dimer is about 2[mu]g/kg to 200 [mu]g/kg (e.g. 10 [mu]g/kg to 45 [mu]g/kg). The invention also provides a method utilizing the application method to treat diseases and provides a drug box, unit dosage and product suitable for any method mentioned by the invention.
PURPOSE:To obtain the titled ointment useful for the remedy of dermatosis caused by trichophyton, e.g. athlete's foot, etc., by adding glacial acetic acid to a base solution containing oxalic acid and broic acid. CONSTITUTION:Small amounts of oxalic acid and boric acid are added to a mixture of sterile water and ethyl alcohol, and the mixture is heated at 90 deg.C to obtain a base solution. The solution is cooled slowly to 55 deg.C, added with glacial acetic acid, and stirred to obtain the objective ointment. Oxalic acid is known to have activity to athlete's foot. Boric acid is added to prevent the damage of the diseased part by the ultrafine powder of oxalic acid, and glacial acetic acid is used to remove the degraded waste horny layer produced by the toxin of trychophyton. The mycelia surrounding the diseased part is floated by the metabolism of the horny layer in the course of treatment, and changes its color first from pale pink color, gradually to pale brown, and finally to the freckle color before falling off from the skin to leave the skin with healthy appearance.
A micro encapsulation material for use with storage unstable, therapeutic and nutritional agents which release the therapeutic and nutritional agents in predetermined locations in the gastro intestinal tract in which the microencapsulation material is formed by combining a food grade treated carbohydrate with a water soluble food grade protein. The therapeutic and nutritional agents form an oil phase which is emulsified with the water dispersed or dissolved encapsulant to encapsulate the therapeutic and nutritional agents. These agents may be oils or oil soluble or oil dispersible. The agents that may be encapsulated include lipids (oils including oxygen sensitive oils, fatty acids, triglycerides) and oil soluble and oil dispersible ingredients (including pharmaceuticals, probiotics, protein therapeutics and bioactives). The protein used may include any film forming water soluble protein or hydrolyzed protein and includes milk proteins such as casein and its derivatives or whey proteins. The carbohydrate component may be those containing reducing sugar groups, oligosaccharides and starches (raw, modified, resistant, acetylated, proprionylated and butylated starches).
Patients receive selumetinib sulfate PO BID on days 1-28. Treatment is continuous and repeats every 28 days for 27 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI throughout the trial.
Men who have sex with men (MSM) bear a greater burden of HIV/AIDS than any other population group in the US, comprising only 2% of the population but 56% of individuals living with HIV/AIDS. Although much of the increased incidence in HIV has been reported among YMSM, especially among racial and ethnic minority groups, and is linked to high-risk sexual behavior, there remains a dearth of evidence-based HIV prevention interventions for YMSM - and none that address racially/ethnically diverse YMSM. To address this need, this study leverages mobile technology and MyPEEPS, an existing theory-driven, multi-ethnic, group-level, evidence-based intervention for diverse YMSM. MyPEEPS is a manualized curriculum, comprised of 6 modules focusing on key intermediate social and personal factors, including knowledge (e.g., correct way to use a condom), self-efficacy for safer sex, interpersonal communication skills and behavioral skills. MyPEEPS is one of the only HIV prevention interventions in the literature that focuses on diverse adolescent MSM. Long-term sustainability of face-to face, group-level behavioral interventions, such as MyPEEPS, have been problematic for dissemination in at-risk populations, particularly among young racial and ethnic minority groups. In response to this challenge, the investigators propose to translate MyPEEPS from a face-to-face, group-based curriculum to a mobile, responsive-driven web-based platform, accessible by smartphone or other web-enabled devices, to increase accessibility and scalability for diverse YMSM. The ubiquitous nature of mobile phones in daily life, especially among 13-18 year olds, has created opportunities for health interventions in a portable format with enhanced privacy. Using a participatory approach, this study will incorporate user-centered design in the translation of the MyPEEPS intervention onto a mobile platform.
Myocardial ischemia/reperfusion (MI/R) injury is a major cause of adverse outcomes of revascularization following myocardial infarction. Anaerobic glycolysis during myocardial ischemia is well studied, but the role of aerobic glycolysis during the early phase of reperfusion is incompletely understood. Lactylation of Histone H3 (H3) is an epigenetic indicator of the glycolytic switch. Heat shock protein A12A (HSPA12A) is an atypic member of the HSP70 family. In the present study, we report that, during reperfusion following myocardial ischemia, HSPA12A was downregulated and aerobic glycolytic flux was decreased in cardiomyocytes. Notably, HSPA12A KO in mice exacerbated MI/R-induced aerobic glycolysis decrease, cardiomyocyte death, and cardiac dysfunction. Gain- and loss-of-function studies demonstrated that HSPA12A was required to support cardiomyocyte survival upon hypoxia/reoxygenation (H/R) challenge and that its protective effects were mediated by maintaining aerobic glycolytic homeostasis for H3 lactylation. Further analyses revealed that HSPA12A increased Smurf1-mediated Hif1α protein stability, thus increasing glycolytic gene expression to maintain appropriate aerobic glycolytic activity to sustain H3 lactylation during reperfusion and, ultimately, improving cardiomyocyte survival to attenuate MI/R injury.
PURPOSE: To obtain a cosmetic for hair washing having excellent color fading- preventive effect on dyed hair, excellent in use feeling and finished feeling by containing polyphenols, an anionic surfactant and/or an amphoteric surfactant and a higher alcohol. CONSTITUTION: This cosmetic contains polyphenols (e.g. gallic acid) and an anionic surfactant (e.g. an alkyl sulfonate) and/or an amphoteric surfactant (e.g. a lauryl dimethylaminoacetate betaine) and a cationic polymer (e.g. a cationic cellulose) as active components. The cosmetic contains 1-50wt.% of the anionic and the amphoteric surfactants and 0.1-1wt.% of the cationic polymer. Otherwise, 0.01-3wt.% of an ultraviolet ray absorber (e.g. benzophenones) and usual optional components are mixed to prepare a shampoo, a rinse, a treatment or a hair cosmetic, etc. This cosmetic for hair washing has suitable viscosity.
Histone deacetylases (HDACs), a class of epigenetic enzymes, play an important role in the pathophysiology of heart failure, including development of left ventricular hypertrophy and myocardial fibrosis. Preclinical data demonstrate the importance of HDAC inhibition in attenuating these pathological processes and maintaining the integrity of the myocardium. However, the role of HDACs in the human heart, and the utility of HDAC inhibition remains unknown. Therefore, a noninvasive method to detect HDAC activity in the human heart in healthy individuals and patients with heart disease may be of major medical and public health value to help determine prognosis, direct therapy, and guide the development of novel therapies for heart failure. The investigators have recently developed a novel radiotracer, 11C-Martinostat, which binds with high affinity to class I HDACs. The objective of this protocol is to assess the utility of 11C-Martinostat PET-MR to detect HDAC expression in the hearts of healthy individuals and patients with severe aortic stenosis or diabetes.